Diagnosis and treatment of vascular dementia
Introduction. Vascular dementia affects between 3.1% and 20.8% of the population aged over 64. Clinical presentation is influenced by personal factors and by disorders associated with cerebrovascular pathology. Objective. Correction of the risk factors and/or modification of the course of the cognitive deterioration would be of considerable benefit to both the patients and their families. Platelet anti-aggregant drugs, which are useful for the prevention of stroke, prevent dementia by correcting this risk factor. Patients and methods. An open study was carried out on a sample of patients with vascular dementia (32 controls and 41 persons treated with triflusal) randomly distributed and followed-up for 12 months. Results. Of the patients who were not treated with triflusal, 33% deteriorated, as did 8% of those treated with triflusal. In the triflusal-treated group. 92% remained above the cut-off line. Conclusions. Therapeutic activity was seen with triflusal, since it stopped cognitive deterioration in patients with vascular dementia
Objetivo Corregir los factores de riesgo y/o modificar el curso del deterioro cognitivo supondrá un importante beneficio para estos pacientes y para sus familiares. Los antiagregantes plaquetarios, útiles en la prevención del ictus, previenen la demencia vascular al corregir este factor de riesgo.
Pacientes y métodos Se realizó un estudio abierto en una muestra de pacientes con demencia vascular (32 controles, 41 tratados con triflusal) distribuidos aleatoriamente y seguidos durante 12 meses.
Resultados El 33% de los pacientes que no recibieron tratamiento con triflusal y un 8% del grupo tratado con triflusal experimentaron una evolución negativa. El 92% de los pacientes tratados con triflusal se mantuvieron por encima del corte establecido.
Conclusiones El triflusal mostró actividad terapéutica al ser capaz de contener el deterioro cognitivo de pacientes con demencia vascular
